It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Proper disinfection and inactivation of highly pathogenic viruses is an essential component of public health and prevention. Depending on environment, surfaces, and type of contaminant, various methods of disinfection must be both efficient and available. To test both established and novel chemical disinfectants against risk group 4 viruses in our maximum containment facility, we developed a standardized protocol and assessed the chemical inactivation of the two Ebola virus variants Mayinga and Makona suspended in two different biological soil loads. Standard chemical disinfectants ethanol and sodium hypochlorite completely inactivate both Ebola variants after 30 s in suspension at 70% and 0.5% v/v, respectively, concentrations recommended for disinfection by the World Health Organization. Additionally, peracetic acid is also inactivating at 0.2% v/v under the same conditions. Continued vigilance and optimization of current disinfection protocols is extremely important due to the continuous presence of Ebola virus on the African continent and increased zoonotic spillover of novel viral pathogens. Furthermore, to facilitate general pandemic preparedness, the establishment and sharing of standardized protocols is very important as it allows for rapid testing and evaluation of novel pathogens and chemical disinfectants.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Federal Office for Civil Protection, Spiez Laboratory, Spiez, Switzerland (GRID:grid.482328.7) (ISNI:0000 0004 0516 7352); Inselspital University Hospital, Department of Rheumatology, Immunology, and Allergology, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855); University of Bern, Department of BioMedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
2 Federal Office for Civil Protection, Spiez Laboratory, Spiez, Switzerland (GRID:grid.482328.7) (ISNI:0000 0004 0516 7352)
3 Federal Office for Civil Protection, Spiez Laboratory, Spiez, Switzerland (GRID:grid.482328.7) (ISNI:0000 0004 0516 7352); University of Lausanne, Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204); Federal Office for Agriculture, Agroscope, Bern, Switzerland (GRID:grid.484687.1) (ISNI: 0000 0001 1457 2921)
4 Federal Office for Civil Protection, Spiez Laboratory, Spiez, Switzerland (GRID:grid.482328.7) (ISNI:0000 0004 0516 7352); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (GRID:grid.424065.1) (ISNI:0000 0001 0701 3136)
5 Federal Office for Civil Protection, Spiez Laboratory, Spiez, Switzerland (GRID:grid.482328.7) (ISNI:0000 0004 0516 7352); ADMED Microbiologie, La Chaux-de-Fonds, Switzerland (GRID:grid.482328.7)